Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus

Journal of Viral Hepatitis

Volumn 22, Issue 4, 2015, Pages 427-432

  Dultz, G ^a   Gerber, L ^a   Farnik, H ^a   Berger, A ^a   Vermehren, J ^a   Pleli, T ^a   Zeuzem, S ^a   Piiper, A ^a   Kronenberger, B ^a   Waidmann, Oliver ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

CD163; fibrosis; hepatitis B virus; Kupffer cell; macrophage; necroinflammation; soluble CD163

Indexed keywords

ANTIVIRUS AGENT; CD163 ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; TENOFOVIR; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS PATHOGENESIS; ADOLESCENT; BLOOD; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; LIVER CIRRHOSIS; MACROPHAGE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MACROPHAGES; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84925395812     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12309     Document Type: Article

References (27)

1. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS,. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-1339.
2. Ganem D, Prince AM,. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
3. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
4. Klein A, Zhadkewich M, Margolick J, Winkelstein J, Bulkley G,. Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing. J Leukoc Biol 1994; 55: 248-252.
5. Rehermann B,. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868.
6. Møller HJ,. Soluble CD163. Scand J Clin Lab Invest 2012; 72: 1-13.
7. Møller HJ, Grønbaek H, Schiødt FV, et al,. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007; 47: 671-676.
8. Ye H, Wang LY, Zhao J, Wang K,. Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure. World J Gastroenterol 2013; 19: 2818-2825.
9. Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B,. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol 2013; 58: 956-961.
10. Waidmann O, Köberle V, Bettinger D, et al,. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol 2013; 59: 769-779.
11. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
12. Waidmann O, Bihrer V, Pleli T, et al,. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19: e58-e65.
13. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
14. Brunetto MR, Oliveri F, Colombatto P, et al,. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
15. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al,. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
16. Wang S, Chen Z, Hu C, et al,. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013; 190: 5142-5151.
17. Fattovich G, Boscaro S, Noventa F, et al,. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155: 931-935.
18. Grégoire C, Chasson L, Luci C, et al,. The trafficking of natural killer cells. Immunol Rev 2007; 220: 169-182.
19. Maini MK, Boni C, Lee CK, et al,. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280.
20. + T-cell immunity. Proc Natl Acad Sci USA 2012; 109: 1210-1215.
21. Rabinovich BA, Li J, Shannon J, et al,. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol 2003; 170: 3572-3576.
22. Peppa D, Gill US, Reynolds G, et al,. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2013; 210: 99-114.
23. Dunn C, Brunetto M, Reynolds G, et al,. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-680.
24. Degos F, Perez P, Roche B, et al,.; FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-1021.
25. Sebastiani G, Castera L, Halfon P, et al,. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther 2011; 34: 1202-1216.
26. Andersen ES, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N,. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study. Eur J Clin Microbiol Infect Dis 2014; 33: 117-122.
27. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.